SLNSW-Trastuzumab emtansine versus treatment of physici...-TN_cdi_proquest_miscellaneous_1900832185

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Full title: Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Author/creator: Krop, Ian E, Dr, Kim, Sung-Bae, Prof, Martin, Antonio Gonzalez, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, MD, Badovinac-Crnjevic, Tanja, MD, Hoersch, Silke, MSc, Smitt, Melanie, MD, Wildiers, Hans, Prof.

Call Numbers:

Record Identifier: TN_cdi_proquest_miscellaneous_1900832185

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1900832185

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Record identifier

    TN_cdi_proquest_miscellaneous_1900832185

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1900832185

    Share

    Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1900832185

    Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Full title

    Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Author / Creator

    Krop, Ian E, Dr ; Kim, Sung-Bae, Prof ; Martin, Antonio Gonzalez, MD ; LoRusso, Patricia M, Prof ; Ferrero, Jean-Marc, MD ; Badovinac-Crnjevic, Tanja, MD ; Hoersch, Silke, MSc ; Smitt, Melanie, MD ; Wildiers, Hans, Prof

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2017, Vol.18 (6), p.743-754

    Record Identifier

    TN_cdi_proquest_miscellaneous_1900832185

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adult Aged Aged, 80 and over Analysis Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms, Male - chemistry Breast Neoplasms, Male - drug therapy Breast Neoplasms, Male - pathology Bridged-Ring Compounds - administration & dosage Cancer therapies Care and treatment Chemotherapy-Induced Febrile Neutropenia - etiology Cytotoxicity Diarrhea Diarrhea - chemically induced Early Termination of Clinical Trials Epidermal growth factor ErbB-2 protein Female Heart Hematology, Oncology and Palliative Medicine Hemorrhage Hemorrhage - chemically induced Hospitals Humans Immunotherapy Male Mammography Maytansine - analogs & derivatives Maytansine - therapeutic use Metastases Metastasis Middle Aged Monoclonal antibodies Motivation Neoplasm Metastasis Nervous system Neutropenia Neutropenia - chemically induced Patient outcomes Patients Physicians Practice Patterns, Physicians Quinazolines - administration & dosage Receptor, ErbB-2 - analysis Retreatment Studies Survival Survival analysis Survival Rate Targeted cancer therapy Taxoids - administration & dosage Thrombocytopenia Thrombocytopenia - chemically induced Trastuzumab Trastuzumab - administration & dosage Ventricle Womens health

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_miscellaneous_1900832185

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1900832185

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections